The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
Open accessAbstract
Background —In a multicenter, double-blind, placebo-controlled study, the long-term effects of amiodarone on morbidity and mortality in patients with congestive heart failure (CHF) and atrial fibrillation (AF) were evaluated during a 4-year period. Methods and Results —Of 667 patients with CHF, 103 (15%) had AF at baseline. Of these, 51 were randomized to amiodarone and 52 to placebo. The group with sinus rhythm and the group in AF were comparable except for a higher proportion of AF in patients with nonischemic versus ischemic cardiomyopathy (41% versus 27%, P <0.005). The mean ventricular response (VR) during AF over 24 hours was reduced by amiodarone at 2 weeks (20%, P =0.001), at 6 months (18%, P =0.001), and at 12 months (16%, P =0.006). Maximal VR was reduced 22% ( P =0.001) at 2 weeks, 19% ( P =0.001) at 6 months, and 14% ( P =0.001) at 12 months. Sixteen of 51 patients on amiodarone and 4 of 52 on placebo converted to sinus rhythm during the study (χ 2 =9.23, P =0.002). During follow-up, 11 of 268 patients in sinus rhythm on amiodarone at baseline and 22 of the 263 in sinus rhythm on placebo developed AF; the difference was significant (χ 2 =12.88, P =0.005). Analysis of total mortality during follow-up showed a significantly lower mortality rate ( P =0.04) in patients in AF at baseline who subsequently converted to sinus rhythm on amiodarone than in those who did not convert to sinus rhythm on the drug. Conclusions —In patients with CHF, amiodarone has a significant potential to spontaneously convert patients in AF to sinus rhythm, with patients who convert having a lower mortality rate than those who do not. The drug prevented the development of new-onset AF and significantly reduced the VR in those with persistent AF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613
Feinberg, W. M. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.5.469 · Cited by 2,274
Krahn, A. D., Manfreda, J., Tate, R. B., Mathewson, F. A. L., & Cuddy, T. E. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80348-9 · Cited by 1,478
Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
Singh, S. N., Fletcher, R. D., Fisher, S. G., Singh, B. N., Lewis, H. D., Deedwania, P. C., Massie, B. M., Colling, C., & Lazzeri, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330201 · Cited by 1,225
Self-citationCoplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 945
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
Flaker, G. C., Blackshear, J. L., McBride, R., Kronmal, R. A., Halperin, J. L., & Hart, R. G. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90003-6 · Cited by 632
Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients.
Middlekauff, H. R., Stevenson, W. G., & Stevenson, L. W. (1991) · Circulation · doi:10.1161/01.cir.84.1.40 · Cited by 578
The effect of amiodarone, a new anti‐anginal drug, on cardiac muscle
SINGH, B. N., & WILLIAMS, E. M. V. (1970) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1970.tb09891.x · Cited by 553
Self-citationPreoperative Amiodarone as Prophylaxis against Atrial Fibrillation after Heart Surgery
Daoud, E. G., Strickberger, S. A., Man, K. C., Goyal, R., Deeb, G. M., Bolling, S. F., Pagani, F. D., Bitar, C., Meissner, M. D., & Morady, F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372501 · Cited by 529
Hohnloser, S. H., Klingenheben, T., & Singh, B. N. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-7-199410010-00009 · Cited by 382
Self-citationCellular electropharmacology of amiodarone
Kodama, I. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00114-4 · Cited by 341
Juul-Möller, S., Edvardsson, N., & Rehnqvist-Ahlberg, N. (1990) · Circulation · doi:10.1161/01.cir.82.6.1932 · Cited by 341
Gosselink, A. T. M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480240051033 · Cited by 281
Atrial Fibrillation Follow-Up Investigation of Rhythm Management—The AFFIRM Study Design
(1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00082-9 · Cited by 266
Amiodarone for refractory atrial fibrillation
Gold, R. L., Haffajee, C. I., Charos, G., Sloan, K., Baker, S., & Alpert, J. S. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90964-1 · Cited by 218
Chun, S. H., Sager, P. T., Stevenson, W. G., Nademanee, K., Middlekauff, H. R., & Singh, B. N. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80799-1 · Cited by 211
Self-citationChronic atrial fibrillation— epidemiologic features and 14 year follow-up: A case control study
ÖNUNDARSON, P. T., THORGEIRSSON, G., JONMUNDSSON, E., SIGFUSSON, N., & HARDARSON, T. (1987) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a062312 · Cited by 187
Horowitz, L. N., Spielman, S. R., Greenspan, A. M., Mintz, G. S., Morganroth, J., Brown, R., Brady, P. M., & Kay, H. R. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80232-1 · Cited by 159
Brodsky, M. A., Allen, B. J., Walker, C. J., Casey, T. P., Luckett, C. R., & Henry, W. L. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90307-9 · Cited by 154
Efficacy of amiodarone for refractory supraventricular tachyarrhythmias
Graboys, T. B., Podrid, P. J., & Lown, B. (1983) · American Heart Journal · doi:10.1016/0002-8703(83)90009-1 · Cited by 125
Atrial fibrillation: Maintenance of sinus rhythm versus rate control
Sopher, S. M., & Camm, A. J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89115-1 · Cited by 118
Ikeda, N., Nademanee, K., Kannan, R., & Singh, B. N. (1984) · American Heart Journal · doi:10.1016/0002-8703(84)90451-4 · Cited by 107
Self-citationNewer developments in the management of atrial fibrillation
Nattel, S. (1995) · American Heart Journal · doi:10.1016/0002-8703(95)90214-7 · Cited by 95
Olsson, S. B., Brorson, L., & Varnauskas, E. (1973) · Heart · doi:10.1136/hrt.35.12.1255 · Cited by 91
Amiodarone in the Management of Refractory Atrial Fibrillation
Blevins, R. D., Kerin, N. Z., Benaderet, D., Frumin, H., Faitel, K., Jarandilla, R., & Rubenfire, M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370080037009 · Cited by 86
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide
Zarembski, D. G. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.17.1885 · Cited by 66
Skoularigis, J. S., Röthlisberger, C., Skudicky, D., Essop, M. R., Wisenbaugh, T. W., & Sareli, P. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)91134-4 · Cited by 53
Expanding Indications for the Use of Class III Agents in Patients at High Risk for Sudden Death
Singh, B. N. (1995) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1995.tb00365.x · Cited by 43
Self-citationControlling Cardiac Arrhythmias: An Overview With a Historical Perspective
Singh, B. N. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00709-1 · Cited by 23
Self-citationClinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia
Koizumi, J., Haraki, T., Yagi, K., Inazu, A., Kalinami, K., Miyamoto, S., Ueda, K., Ohta, M., Takegoshi, T., TAKEDA, M., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80016-5 · Cited by 20
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Metadata
- Authors
- Deedwania, P. C., Singh, B. N., Ellenbogen, K., Fisher, S., Fletcher, R., & Singh, S. N.
- Venue
- Circulation
- Published
- 1998-12-08
- Volume
- 98
- Issue
- 23
- Pages
- 2574-2579
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2020509502
- Cited by
- 506
- References
- 31
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.